Nicolas Perez Maldonado, MD
Neurology · Bayamon, PRNPI 1558354829
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,093 of the $4,563 with a category attached, or 67.8%. 13 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 33.9% of the total. Reporting peaked in 2021 at $1,771 and has fallen 83.7% since, to $289 in 2025.
Across 169 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Biogen$1K
- Novartis$608
- Genentech USA, Inc.$451
- TG Therapeutics, Inc.$151
- Sanofi$128
- plus $361 from 7 others
What the payments were for
- Consulting fees$1,46032%
- Food & beverage$3,09368%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $1,546 |
| Biogen | 75 | $1,317 |
| Novartis | 26 | $608 |
| Genentech USA, Inc. | 32 | $451 |
| TG Therapeutics, Inc. | 6 | $151 |
| Sanofi | 6 | $128 |
| AbbVie | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Johnson & Johnson | 3 | $67 |
| Banner Life Sciences, LLC | 2 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $47 |
| UCB, Inc. | 1 | $32 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $18 |
How this compares
$4,563 in reported general payments places this provider in the 70th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 41 | $378,851 |
| VumerityDiroximel Fumarate | 35 | $336,862 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 39 | $335,548 |
| AmpyraDalfampridine | 26 | $111,918 |
| MayzentSiponimod | 11 | $110,284 |
| Avonex (4 Pack)Interferon Beta-1a | 12 | $98,496 |
| TysabriNatalizumab | 11 | $90,960 |
| KeppraLevetiracetam | 79 | $85,926 |
| Emgality PenGalcanezumab-Gnlm | 61 | $74,235 |
| CopaxoneGlatiramer Acetate | 11 | $62,354 |
| LamictalLamotrigine | 55 | $39,478 |
| Dalfampridine ErDalfampridine | 151 | $18,954 |
| Tegretol XrCarbamazepine | 52 | $16,260 |
| RytaryCarbidopa/Levodopa | 27 | $9,608 |
| DepakoteDivalproex Sodium | 26 | $7,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Avonex (4 Pack), Tysabri | $1,317 | $526,31758 claims |
| NovartisMayzent | $608 | $110,28411 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $72 | $62,35411 claims |
| AbbVieSynthroid | $73 | $87115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Bayamon
- Horacio Daubon-Del ValleBayamon$21K
- Melissa Mendez MoralesBayamon$6K
- Carlos Barreto MirandaBayamon$4K
- Olga RiosBayamon$4K
- Luis Rivera RamosBayamon$2K
- Rene Sanchez BorreroBayamon$2K
- Angel ChineaGuaynabo$1.7M
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.